Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Stuart Green | M | 58 |
University of Bristol
| 6 años |
| Mohammad Sharif Ali Sharif Al-Zoubi | M | 61 |
University of Bristol
| 1 años |
| George Poste | M | 79 |
University of Bristol
| 3 años |
| Carolyn Christie | F | 65 |
University of Bristol
| 4 años |
| Michael McGuigan | M | - |
University of Bristol
| 4 años |
| John Whitebrook | M | - |
University of Bristol
| 3 años |
| Phil Taylor | M | - |
University of Bristol
| 4 años |
| Yusuf bin Jamil | M | 60 |
University of Bristol
| 4 años |
| Nick Fry | M | - |
University of Wales (Bangor)
| 4 años |
| Andrew Oliver Mullins | M | 60 |
University of Bristol
| 4 años |
| Alan R. Nicholl | M | - |
University of Bristol
| 4 años |
| Phil Ivey | M | - |
University of Bristol
| 4 años |
| Clive Banks | M | - |
University of Bristol
| 4 años |
| Donald Charles McQueen | M | 62 |
University of Bristol
| 4 años |
| James Greenwood | M | 60 |
University of Bristol
| 3 años |
| David Anthony Littlewood | M | 58 |
University of Bristol
| 3 años |
| Kay Nichols | F | - |
University of Bristol
| 3 años |
| Frederick Jones | M | - |
BioRexis Pharmaceutical Corp.
 BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | - |
| Andrew Mullins | M | - |
University of Bristol
| 4 años |
| David Maguire | M | - |
University of Bristol
| 3 años |
| Nigel Spray | M | - |
University of Bristol
| 3 años |
| Christine Whyte | M | - |
University of Bristol
| 3 años |
| Charles Edward Beck Bowman | M | 63 |
University of Bristol
| 4 años |
| Roger Blott | M | - |
University of Bristol
| 3 años |
| Sarah Brown | F | 60 |
University of Bristol
| 3 años |
| Daniel Newman | M | 64 |
University of Bristol
| 4 años |
| David B. Morris | M | 57 |
University of Bristol
| 4 años |
| Adam Hale | M | 59 |
University of Bristol
| 3 años |
| Rhodri Glyn Thomas | M | 71 |
University of Wales (Bangor)
| 4 años |
| Mark Gino Francois | M | 58 |
University of Bristol
| 4 años |
| Clive Stuart Brown | M | 64 |
University of Bristol
| 3 años |
| Matthew Tossell | M | - |
University of Wales (Bangor)
| 3 años |
| Roger Murphy | M | - |
University of Wales (Bangor)
| 4 años |
| Wai Man Chu | M | 59 |
University of Bristol
| 3 años |
| David Michael Foulds | M | - |
University of Bristol
| 4 años |
| Charles Edwardes-Ker | M | - |
University of Bristol
| 4 años |
| Michael Celano | M | 65 |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 3 años |
| Mark Poole | M | 60 |
University of Bristol
| 4 años |
| Quintin Price | M | 63 |
University of Bristol
| 4 años |
| Edwin Harless | M | 77 |
Aventis Behring
| 3 años |
| Richard Cunningham | M | 64 |
University of Bristol
| 3 años |
| Michael Lindsell | M | 64 |
University of Bristol
| 4 años |
| Andrew McIver | M | 61 |
University of Bristol
| 4 años |
| Paul McGroary | M | 66 |
University of Wales (Bangor)
| 4 años |
| Robert Barker | M | 61 |
University of Bristol
| 4 años |
| Warren Tucker | M | 61 |
University of Bristol
| 4 años |
| Nick Bertolotti | M | 62 |
University of Bristol
| 4 años |
| Richard M. Campbell-Breeden | M | 62 |
University of Bristol
| 4 años |
| David Scott | M | 62 |
University of Bristol
| 4 años |
| Asish Xavier | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 1 años |
| Royston Stephen Ferris | M | 64 |
University of Bristol
| 4 años |
| Frederick Jones | M | - |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | 3 años |
| Stephen Dewhurst | M | - |
University of Bristol
| 3 años |
| Henry Sallitt | M | 62 |
University of Bristol
| 3 años |
| Ray N. Simpson | M | - |
University of Bristol
| 4 años |
| Sally Caroline Powell | F | - |
University of Bristol
| 3 años |
| Michael Greville | M | - |
University of Bristol
| 4 años |
| David Roy Ettle | M | - |
University of Bristol
| 4 años |
| Mark John Tomlinson | M | - |
University of Wales (Bangor)
| 4 años |
| Timothy Moore | M | 62 |
Aventis Behring
| 4 años |
| Jeremy K. Llewelyn | M | - |
University of Bristol
| 4 años |
| Hang Fong Lo | M | 54 |
University of Bristol
| 3 años |
| T. Ben Hsu | M | - |
Aventis Behring
| 4 años |
| David Srodzinski | M | - |
University of Bristol
| 4 años |
| Alex Donnison | M | - |
University of Wales (Bangor)
| 4 años |
| Sean W. Lanigan | M | - |
University of Wales (Bangor)
| 1 años |
| Mohamed Nazir bin Abdul Razak | M | 58 |
University of Bristol
| 4 años |
| Wai Ha Tang | F | 60 |
University of Bristol
| 4 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Reino Unido | 61 | 89.71% |
| Estados Unidos | 7 | 10.29% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- James Ballance
- Red Personal
